The SIRA RFA Electrosurgical Device is specifically designed for use in breast cancer patients, who are undergoing breast-conserving surgery. Credit: Innoblative Designs/PRNewswire.

The US Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Innoblative Designs’ SIRA RFA Electrosurgical Device.

SIRA has been specifically designed for use in breast cancer patients who are undergoing breast-conserving surgery (BCS), which is commonly referred to as lumpectomy.  

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It has a unique spherical shape that allows circumferential delivery of radiofrequency (RF) energy.

The device delivers RF energy to the entire cavity and enables reproducible action depths. This provides greater confidence in a consistent thermal effect, the company said.

In several long-term clinical trials, RF ablation was found to reduce reoperations as well as local recurrence in breast cancer treatment.

Innoblative CEO Richard Stark said: “Receiving a breakthrough designation is a significant achievement and I congratulate the team for their efforts to reach this important milestone.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We believe the SIRA will be a game changer in BCS for breast cancer and we look forward to bringing this important technology to cancer patients.”

The SIRA device features a 4cm diameter spherical electrode which creates a wide ablation zone that covers a large surface area per ablation.

It is claimed to safely facilitate the accurate removal of clinical targets.

It has a larger applicator that helps avoid painting a tissue surface and physician-controlled settings will allow to customise ideal ablation performance.

Dr Thomas Frazier, medical director at Bryn Mawr Hospital Pennsylvania Comprehensive Breast Center, said: “The SIRA technology is an exciting advancement in the treatment of breast cancer as it is designed to allow surgeons to address potential residual cancer in the lumpectomy cavity at the time of the initial procedure.

“Designed to augment the lumpectomy procedure, the SIRA device aims to reduce the need for reoperations.”